- Poster presentation
- Open Access
Significant hypophosphatemia following major cardiac surgery: incidence and consequences
Critical Care volume 8, Article number: P266 (2004)
Significant hypophosphayemia (SH) may be associated with respiratory and cardiac complications but has not been targeted as a reversible cause of these complications following cardiac surgery.
Patients and methods
We prospectively studied all patients (n = 566, males 388, females 178, mean age 65.5 [11.1] years) undergoing major cardiac surgery (coronary artery bypass grafting [CABG] 75.4%; aortic valve replacement 5.1%; aortic valve replacement + CABG 5.8%; mitral valve replacement 6.8%; other 6.9%) over a 6-month period. Phosphate levels were measured preoperatively, on admission to the ICU, and on the first postoperative day. Two groups were defined according to the ICU admission level: SH, level <0.48 mmol/l; and a control group, normal range 0.8–1.45 mmol/l. Preoperative, intraoperative and postoperative data were collected in all patients. SH was treated with intravenous sodium or potassium phosphate (0.08 mmol/kg) over 6–12 hours.
As SH after cardiac surgery appears to be common and associated with major morbidity, levels should be routinely monitored.
About this article
Cite this article
Cohen, J., Kogan, A., Sahar, G. et al. Significant hypophosphatemia following major cardiac surgery: incidence and consequences. Crit Care 8, P266 (2004). https://doi.org/10.1186/cc2733
- Mitral Valve
- Coronary Artery Bypass Grafting
- Artery Bypass
- Coronary Artery Bypass
- Bypass Grafting